Nicholas Thomas
City University of Hong Kong(HK)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, Pancreatic function and diabetes, Diabetes and associated disorders, Diabetes Management and Research, Long-Term Effects of COVID-19
Most-Cited Works
- → Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial(2022)395 cited
- → Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)307 cited
- → Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)303 cited
- → Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England(2020)87 cited
- → The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms(2020)78 cited
- → Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)77 cited
- → Human security and public health in Southeast Asia: the SARS outbreak(2004)74 cited
- → Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes(2024)59 cited
- → d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women(2024)52 cited
- → Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial(2022)51 cited